EUCTR2018-001481-42-ES进行中（未招募）1 期
Prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of a 0.005% estriol vaginal gel in the prevention of recurrent urinary tract infections in postmenopausal women with vaginal atrophy. BLISSURE study - BLISSURE
ITF RESEARCH PHARMA S.L.U.0 个研究点目标入组 120 人开始时间: 2018年9月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Women between 55 and 75 years old.
- •2. Postmenopausal women (who have at least 12 months without menstruation) by natural process or by surgical intervention.
- •3. Women with vaginal dryness.
- •4. Women with a history of episodes of symptomatic UTIs of:
- •4a) at least 3 episodes of UTIs in the last 12 months or
- •4b) at least 2 episodes of UTIs in the last 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. Women with presence of symptomatic urinary infection confirmed microbiologically by uroculture of the sample taken during the screening visit.
- •2. Women with asymptomatic bacteriuria determined by urine culture of the sample taken at the screening visit.
- •3. Women with a history of malignant or premalignant lesions in breast or endometrium, malignant colon or hepatic tumors, malignant melanoma, venous thromboembolic disorders (deep vein thrombosis, pulmonary embolism) or arterial thromboembolic disorders (cardiac ischemia, myocardial infarction, cerebrovascular accident ), peripheral arterial disease, thrombosis of the mesenteric artery, thrombosis of the renal artery or coagulopathies.
- •4. Women with vaginal bleeding of unknown etiology.
- •5. Women who have received any type of vulvovaginal treatment in the 15 days prior to the start of the study treatment (baseline visit).
- •6. Women who received phytoestrogens within 1 month before the start of the study treatment (baseline visit), including vaginal administration.
- •7. Women who have received hormone therapy in the 3 months before the start of the study treatment (baseline visit), including the vaginal administration of estrogens.
- •8. Women who are being treated with estrogen or progestin, tibolone or selective modulators of the estrogen receptor, antiepileptic and urinary antiseptics.
- •9. Women who have received long-term antibiotic treatment (for two or more weeks) in the last 3 months before the start of the study treatment.
- •10. Women with anatomical or functional injuries of the urogenital tract.
- •11. Women with permanent urinary catheter.
- •12. Women diagnosed with diabetes mellitus.
- •13. Women diagnosed with severe renal or hepatic failure.
- •14. Women with neurological pathologies.
- •15. Immunosuppressed women.
- •16. Women with vesicoureteral reflux.
- •17. Women with urinary incontinence due to overactive bladder.
- •18. Women who are currently participating or have participated in the last 3 months in another clinical trial.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to assess the efficacy and safety of a vaccine for grasses and olive tree allergyAetiological treatment of moderate-severe intermitent or persistent allergic rhinitis/rhinoconjunctivitis with or without controlled mild-moderate intermittent or persistent allergic asthmaMedDRA version: 20.0Level: LLTClassification code: 10036019Term: Pollen allergy Class: 10021428MedDRA version: 26.0Level: LLTClassification code: 10034382Term: Perennial allergic rhinitis Class: 10038738MedDRA version: 27.0Level: LLTClassification code: 10070526Term: Grass allergy Class: 10021428MedDRA version: 20.0Level: LLTClassification code: 10001728Term: Allergic rhinoconjunctivitis Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10001705Term: Allergic asthma Class: 10038738CTIS2024-514525-34-00Inmunotek S.L.180
进行中（未招募）
1 期
Clinical trial to asses the efficacy and safety of a vaccine for grasses and cupressaceae allergyAetiological treatment of moderate-severe intermitent or persistent allergic rhinitis/rhinoconjunctivitis with or without controlled mild-moderate intermittent or persistent allergic asthmaMedDRA version: 27.0Level: LLTClassification code: 10070526Term: Grass allergy Class: 10021428MedDRA version: 26.0Level: LLTClassification code: 10034382Term: Perennial allergic rhinitis Class: 10038738MedDRA version: 20.0Level: LLTClassification code: 10001728Term: Allergic rhinoconjunctivitis Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10001705Term: Allergic asthma Class: 10038738MedDRA version: 20.0Level: LLTClassification code: 10036019Term: Pollen allergy Class: 10021428CTIS2024-514524-16-00Inmunotek S.L.180
进行中（未招募）
1 期
Dose-response study of efficacy and safety of Botulinum toxin type A to treat spasticity of the arm(s) or of arm(s) and leg(s) in cerebral palsypper limb spasticity or combined upper and lower limb spasticity in children and adolescents(age 2 - 17 years) with cerebral palsyMedDRA version: 19.1Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852EUCTR2012-005496-14-Outside-EU/EEAMerz Pharmaceuticals GmbH344
进行中（未招募）
1 期
Dose-response study of efficacy and safety of Botulinum toxin type A to treat spasticity of the leg(s) in cerebral palsyower limb spasticity due to cerebral palsyMedDRA version: 17.1Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852EUCTR2012-005054-30-SKMerz Pharmaceuticals GmbH300
进行中（未招募）
1 期
Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacksacute hereditary angioedema attacksMedDRA version: 20.0Level: LLTClassification code: 10075280Term: Hereditary angioedema attack Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080960Term: Hereditary angioedema type II Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080957Term: Hereditary angioedema C1 inhibitor deficiency Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080956Term: Hereditary angioedema type I Class: 10010331CTIS2023-503507-29-00Octapharma Pharmazeutika Produktionsgesellschaft mbH124